{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T23:04:17Z","timestamp":1774134257987,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":2524,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1111\/j.1469-0691.2007.01864.x","type":"journal-article","created":{"date-parts":[[2008,2,8]],"date-time":"2008-02-08T12:29:04Z","timestamp":1202473744000},"page":"181-184","source":"Crossref","is-referenced-by-count":54,"special_numbering":"S1","title":["Antibiotic policy and prescribing strategies for therapy of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: the role of piperacillin\u2013tazobactam"],"prefix":"10.1016","volume":"14","author":[{"given":"L.R.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2007.01864.x_bib1","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/319757","article-title":"Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes","volume":"32","author":"Lautenbach","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib3","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1128\/AAC.46.5.1481-1491.2002","article-title":"Bloodstream infections by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome","volume":"46","author":"Kim","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003495-200363040-00002","article-title":"Extended spectrum \u03b2-lactamases (ESBL)-producing Enterobacteriaceae","volume":"63","author":"Rupp","year":"2003","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib5","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1128\/AAC.48.12.4574-4581.2004","article-title":"Bloodstream infections due to extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy","volume":"48","author":"Kang","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of \u03b2-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib7","series-title":"Performance standards for antimicrobial disk susceptibility testing","author":"Clinical and Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards)","year":"2005"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/AAC.50.2.498-504.2006","article-title":"Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome","volume":"50","author":"Tumbarello","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib9","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin\u2013tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/508877","article-title":"Bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge","volume":"43","author":"Rodr\u00edguez-Ba\u00f1o","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/clinids\/23.1.118","article-title":"Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center","volume":"23","author":"Rice","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1128\/AAC.42.1.53","article-title":"Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases","volume":"42","author":"Pe\u00f1a","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib13","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1086\/514743","article-title":"Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary","volume":"28","author":"Landman","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1086\/501787","article-title":"Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae","volume":"21","author":"Patterson","year":"2000","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib15","first-page":"182","article-title":"Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms","volume":"36","author":"Lan","year":"2003","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1128\/AAC.48.2.392-395.2004","article-title":"Replacement of broad-spectrum cephalosporins by piperacillin\u2013tazobactam: impact on sustained high rates of bacterial resistance","volume":"48","author":"Bantar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bcp.2005.11.012","article-title":"Understanding the longevity of the beta-lactam antibiotics and of antibiotic\/beta-lactamase inhibitor combinations","volume":"71","author":"Buynak","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib18","doi-asserted-by":"crossref","first-page":"46601","DOI":"10.1074\/jbc.M207884200","article-title":"Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin","volume":"277","author":"Shimamura","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tim.2006.07.008","article-title":"The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter","volume":"14","author":"Livermore","year":"2006","journal-title":"Trends Microbiol"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib20","first-page":"9","article-title":"Inactivation of beta-lactamases by sulbactam and enhanced clinical activity due to target-site binding of the combination of sulbactam and ampicillin","volume":"5","author":"Yokota","year":"1989","journal-title":"APMIS Suppl"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib21","first-page":"200","article-title":"Molecular correlation between in vitro and in vivo activity of beta-lactam and beta-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus","volume":"125","author":"Fasola","year":"1995","journal-title":"J Lab Clin Med"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib22","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1128\/JCM.43.10.5048-5054.2005","article-title":"Clinical and molecular analysis of extended-spectrum beta-lactamase-producing enterobacteria in the community setting","volume":"43","author":"Arpin","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2003.12.019","article-title":"Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)","volume":"24","author":"Streit","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.diagmicrobio.2004.11.013","article-title":"Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997\u20132002)","volume":"51","author":"Turner","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.diagmicrobio.2006.08.016","article-title":"Comparative activities of cefepime and piperacillin\/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype","volume":"57","author":"Sader","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01864.x_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.idc.0000195907.84587.c0","article-title":"Does identification of an extended spectrum beta-lactamase (ESBL) producing organism by the microbiology laboratory influence patient management?","volume":"14","author":"Gavin","year":"2006","journal-title":"Infect Dis Clin Pract"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14604912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14604912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T19:46:26Z","timestamp":1557258386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14604912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":26,"alternative-id":["S1198743X14604912"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01864.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}